Trial reportBone marrow transplantation2015
A multigene array for measurable residual disease detection in AML patients undergoing SCT.
Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.Haematologica · 2017Pooled it
- Trial
- Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.Acta haematologica · 2024Review
- Review
- Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation.Cancers · 2022Article
- Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?Current oncology reports · 2021Review
- Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.Haematologica · 2019Article
- Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.Frontiers in oncology · 2018Article
- The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.Current hematologic malignancy reports · 2017Review
- Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.Leukemia research · 2017Review
- Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.Journal of clinical medicine · 2017Review
- Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Blood reviews · 2017Review
- Review
- Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Journal of clinical medicine · 2017Review
- Antibody darts on target for acute myelogenous leukemia.Annals of translational medicine · 2017Article
- Minimal Residual Disease in Acute Myeloid Leukemia.Current treatment options in oncology · 2017Review
- Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Article
- Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Leukemia & lymphoma · 2016Review
- Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies.Therapeutic advances in hematology · 2016Review
- Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.Mediterranean journal of hematology and infectious diseases · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
AML is a diagnosis encompassing a diverse group of myeloid malignancies. Heterogeneous genetic etiology, together with the potential for oligoclonality within the individual patient, have made the identification of a single high-sensitivity marker of disease burden challenging. We developed a multiple gene measurable residual disease (MG-MRD) RQ-PCR array for the high-sensitivity detection of AML, retrospectively tested on 74 patients who underwent allo-SCT at the NHLBI in the period 1994-2012. MG-MRD testing on peripheral blood samples prior to transplantation demonstrated excellent concordance with traditional BM-based evaluation and improved risk stratification for post-transplant relapse and OS outcomes. Pre-SCT assessment by MG-MRD predicted all clinical relapses occurring in the first 100 days after allo-SCT compared with 57% sensitivity using WT1 RQ-PCR alone. Nine patients who were negative for WT1 prior to transplantation were correctly reclassified into a high-risk MG-MRD-positive group, associated with 100% post-transplant mortality. This study provides proof of principle that a multiple gene approach may be superior to the use of WT1 expression alone for AML residual disease detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.